back arrowBack To Resources

Why the Highest Offer Isn’t Always the One I’d Recommend

When offers start coming in, many sellers do the same thing. Their eyes go right to the purchase price, and the offer with the highest headline number feels like the obvious choice. That’s a completely natural reaction. You’ve spent years building your practice, and that number can feel like the final score on all of your hard work.

But as a deal captain involved in active deals every day, I’ve seen firsthand why the highest offer isn’t always the best one. I work closely with sellers, field calls from buyers, and dissect every letter of intent that crosses my desk. Across our team’s $1.5B in completed transactions and 200+ deals, we’ve seen this lesson play out time and time again.

The reason is simple: the price on a letter of intent isn’t necessarily what you take home. The terms behind an offer can quietly change what it’s actually worth, and many sellers don’t know what to look for. That’s why evaluating an offer means looking beyond the headline number to understand what you’re actually getting, how much of that value is certain, and what you’re agreeing to in return. Ultimately, the best offer is the one that delivers the most certain value, on terms you can live with, from a buyer who will actually close the deal.

The Headline Number Is the Tip of the Iceberg

Behind every purchase price is a mix of payments and terms that don’t all carry the same weight. Some arrive on closing day, some depend on what happens years later, and some shape what you can do after the sale. When an LOI comes in, here’s what I look at first:

  • Cash at close. This is the money that reaches your account on closing day. It’s the most certain dollar in any deal, which is why it’s the first number I look at.
  • Rollover equity. This is the portion of your value you keep as ownership in the buyer’s platform. It can offer real upside, but what it’s ultimately worth depends on how that platform performs and when it eventually sells.
  • Earnouts. These are payments tied to hitting future targets. When the targets are aggressive or depend on factors outside your control, there’s a chance that money never materializes.
  • Holdbacks and escrow. A portion of the price is set aside after closing to cover potential claims or adjustments. That’s standard practice, but how much is held, and for how long, can meaningfully change what you walk away with.
  • Working capital target. Many deals set a benchmark for the receivables, supplies, and other day-to-day operating assets, net of short-term liabilities, that the practice is expected to deliver at closing. If you come in below it, the shortfall typically comes out of your proceeds.
  • Your employment agreement. This covers how many years you’re committing to, how you’ll be compensated, and what happens if you want to step back. It’s part of the deal’s value, whether or not it’s priced that way.
  • Non-compete. This defines how far, how long, and what kind of work you agree not to do after the sale. A broad non-compete can limit your options for years, particularly if the partnership doesn’t work out as planned.

None of these terms is a problem on its own, and rollover in particular has worked out very well for many of our past clients. The problem is when most of a large offer is money that isn’t guaranteed. You could walk away from closing with no more cash than a smaller offer would have given you, and with less favorable terms attached.

A Recent Deal Where the Biggest Number Lost

I saw this play out on a recent deal. We took a general dentistry practice to market, and one buyer submitted an offer with a multiple well above the rest of the group. On a summary sheet, it looked like the clear winner, and it was the kind of number that gets everyone’s attention.

Once I dug into the structure, the picture changed. Only about half of the price was paid as cash at close. A large piece came as a seller note, paid out over several years, unsecured, and ranked behind the buyer’s bank debt. Another large piece was rollover equity with no clear date for when it would turn into cash, since the buyer expected owners who were still working to roll their equity again in a future recapitalization instead of cashing out. On top of that, the growth bonus was built so the practice would have had to grow its earnings dramatically in just two years to collect it in full, and the first stretch of growth earned nothing at all. Altogether, more than half of the deal was either deferred or at risk.

As I walked the seller through what that offer would look like on closing day, and again a few years down the road, their enthusiasm faded. When we compared it side by side with another offer that had a lower headline number, the lower offer actually put more cash in the seller’s pocket at closing, even after fees and taxes. The seller pushed for a larger share of cash at close, but the buyer held firm on its structure. In the end, they weren’t comfortable betting that much of their value on a long-term note and equity with no clear exit, so they passed on that offer.

The buyer didn’t do anything wrong; they built an offer that worked for them. My role was to make sure the seller understood the full offer before becoming attached to the headline number.

Why Buyers Build Offers This Way

In most cases, this isn’t about buyers being deceptive. A DSO or private equity-backed platform works within a budget and a target return, and deal structure is how they make the two fit. Shifting value into earnouts and rollover allows a buyer to present a larger number while moving more of the risk onto the seller.

There’s a competitive element as well. Buyers know the headline price is the first thing sellers compare, and a strong multiple can earn them attention, a spot in the next round, and sometimes exclusivity. Once an LOI is signed and the exclusivity period begins, your leverage drops considerably, and that’s often when the finer details of the offer come into focus.

That’s why I prefer to pressure-test every offer before a seller becomes emotionally invested in it, rather than after.

A Great Offer Only Matters if It Closes

The other half of my recommendation has little to do with the numbers. I would rather see a seller accept a good offer from a buyer who closes on the terms in their LOI than a great offer from a buyer known for retrading during due diligence. A retrade, where the buyer lowers the price or reworks the terms after you’ve committed, can erase the difference between two offers in a single conversation.

Additionally, fit matters just as much, and it’s easy to overlook when a large number is on the table. That means looking at how much clinical autonomy you’ll keep, how the buyer treats the teams it brings on, and how its other affiliated owners feel a few years after closing. You’ll likely work alongside this partner for years, and a slightly lower offer from a partner you trust will usually serve you better than a higher one you come to regret.

How We Weigh Offers Side by Side

When offers come in, we don’t simply pass along a stack of LOIs. We lay every offer out on the same terms so you can compare them side by side, starting with what you’ll actually take home at closing and what remains at risk afterward.

From there, we pressure-test the details that are easy to overlook, including whether earnout targets are realistic for your practice, how rollover equity might perform under different scenarios, and how each buyer has behaved in past transactions. We also go back to buyers before anything is signed, because the best time to improve structure is while they’re still competing for your practice, not after exclusivity begins.

Sometimes that process confirms the highest offer truly is the best one, which is a great outcome. Other times, as with the deal I described earlier, it reveals that the biggest number comes with strings a seller isn’t willing to accept. Either way, you make the decision with the full picture in front of you.

Have an Offer in Hand? We’ll Take a Look

If you have an LOI in hand, or several, and you’re not what they’re really worth, we’re happy to take a look. Reach out at [email protected] or visit www.TuskPracticeSales.com to set up a conversation with our team.

Frequently Asked Questions

How do I know if a buyer is the right fit for my practice?

Look beyond the price at how much clinical autonomy you’ll keep, how the buyer treats the teams it brings on, and how its affiliated owners feel a few years after closing. You’ll likely work alongside this partner for years, so a slightly lower offer from a buyer you trust will often serve you better than a higher one you come to regret.

Can I negotiate the structure of an offer after I sign the LOI?

You can, but your leverage drops considerably once the LOI is signed and exclusivity begins, because the buyer is no longer competing for your practice. The best time to improve terms like cash at close or earnout targets is before you sign.

What is a retrade, and how can it affect my deal?

A retrade happens when a buyer lowers the price or reworks the terms after you’ve signed the LOI, often during due diligence. A single retrade can wipe out the difference between two competing offers, which is why a buyer’s closing track record matters as much as their headline number.

Yazen Abusad, Director at TUSK Practice Sales

About the author

Yazen Abusad

Director, TUSK Practice Sales

Yazen Abusad is a Director at TUSK Practice Sales. He helps lead TUSK's M&A advisory engagements, working with healthcare practice owners to capture the full value of what they have built and to identify opportunities for growth. Before joining TUSK, he was a Vice President at Generational Group, a middle-market M&A investment banking firm, where he worked on sell-side exit strategies. He holds a Master's in Finance and a Bachelor's in Biochemistry from Southern Methodist University.